|
|
Article: NeoPharm Receives Orphan Drug Status for IL13-PE38 for the Treatment of Malignant Glioma.
- Article from:
- Business Wire
- Article date:
- November 26, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors
LAKE FOREST, Ill.--(BUSINESS WIRE)--Nov. 26, 2001
Orphan drug status may help to decrease time to
market for brain cancer treatment
NeoPharm, Inc. (Nasdaq National Market: NEOL) announced today that its novel tumor-targeting agent - IL13-PE38 - was granted orphan drug status from the U.S. Food and Drug Administration (FDA) for the treatment of malignant glioma, a terminal brain cancer for which there is no known cure. NeoPharm has exclusively licensed IL13-PE38 from the National Cancer Institute and the FDA, and is developing the compound under a Cooperative Research and Development Agreement (CRADA) with the FDA.
...